Advanced Search
Disease Phase
Title Drug
Clinical Trials Listing
  • < Previous
  • 1
  • Next >
  • Penn Treatment Trials (8)
  • Penn Non-Treatment Trials (6)
  • Phase 1: Solid Tumor Trials (3)
  • Proton Therapy Trials (1)
Active treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
TS-102 A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy III Radiotherapy Not Applicable
UPCC 05209 A Phase II/Pharmacodynamic Study of Preoperative or Definitive FOLFOX Plus Bevacizumab, With the Additional Pharmacodynamic Goal of Assessing Tumor Blood Flow as Measured by Dynamic Contrast-enhanced MRI, and the Induction of Hypoxia and Apoptosis as Measured by PET in Patients With Rectal Cancer II Angiogenesis Inhibitor, Imaging Procedure bevacizumab
Onconova 09-09 A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma II Signal Transduction Inhibitor rigosertib
GO28074 A Phase II, Multicenter, Open-Label, Randomized Study Evaluating the Efficacy and Safety of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wildtype Metastatic Colorectal Cancer II Chemotherapy, Immunotherapy (Monoclonal Antibody), EGFR Inhibitor, Topoisomerase Inhibitor fluorouracil; irinotecan; cetuximab; leucovorin ; MEHD7945A (RG7597)
UPCC-07210 A Phase I/II Pharmacodynamic Study of Hydroxychloroquine in Combination With FOLFOX Plus Bevacizumab to Inhibit Autophagy in Colorectal Cancer I / II Angiogenesis Inhibitor, Chemotherapy, Other oxaliplatin; fluorouracil; bevacizumab; leucovorin ; hydroxychloroquine
CLDE225A2112 A Phase Ib, Multi-center, Two Parallel Group, Open-label, Drug-drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients With Advanced Solid Tumors I Other warfarin; bupropion
CA186-011 A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of BMS-663513 (Anti-CD137) in Subjects With Advanced and/or Metastatic Solid Tumors I Immunotherapy BMS-663513
UPCC - 13212 A Phase 1 Study of LY2801653 in Patients With Advanced Cancer I c-MET Inhibitor LY2801653
Displaying: 1 - 8 of 8 Results
  • < Previous
  • 1
  • Next >